Micromonospora sp. biobank exploration for novel biopesticide discovery

Overview

This research collaboration opportunity focuses on exploring Micromonospora sp. bacteria as a source of novel biopesticides. Micromonospora species are well-established producers of aminoglycoside antibiotics, including gentamicin, sisomicin, and the recently discovered turbinmicin. The project leverages a unique 25-year biobank of well-characterized strains, studied under both laboratory and field conditions, to identify new antimicrobial compounds that can support sustainable agriculture and improve soil health.

The initiative addresses the growing need for biobased solutions to plant pathogens, offering a pathway to develop proprietary microbial agents that can replace or complement conventional chemical pesticides. The work combines microbiology, genomics, and bioinformatics to unlock the biosynthetic potential of these under-explored soil bacteria.

Technical specifications

Research approach:

• Screening of Micromonospora sp. strains from a proprietary biobank with 25 years of characterization data
• Detailed DNA sequencing and bioinformatics analysis of gene clusters responsible for antimicrobial production
• Identification of novel biopesticide candidates through genomic mining of biosynthetic pathways
• Active compound extraction and overexpression studies in collaboration with industry partners
• Plant-based testing to validate efficacy against target pathogens

Key capabilities:

• Access to a unique, well-documented strain collection with known laboratory and field performance
• Expertise in fundamental bio- and phytoremediation research
• Cross-disciplinary analytical capabilities spanning microbiology, genomics, and environmental sciences
• Established track record in industrial collaboration for sustainable agriculture solutions

Technology readiness level

The project is at an early-to-mid research stage, building on validated foundational work. The biobank strains have been characterized over 25 years under both lab and field conditions, providing a strong starting point. The current phase involves developing proprietary microbial agents and conducting detailed genomic and bioinformatics analyses of pathogen-relevant gene clusters. Subsequent validation steps, including compound extraction, overexpression studies, and plant tests, are planned in collaboration with industry partners. The research is positioned to advance from discovery toward applied agricultural applications with appropriate co-development partnerships.